Chai Discovery vs Cradle
Both sell protein design as software rather than as a discovery partnership, which already separates them from most of this category, and they differ in what they have chosen to make public. Chai releases named, versioned models with a documented history, quantifies its wet laboratory validation including how many targets were attempted and how many designs were tested, and holds the most complete governance posture in this category, backed by an action rather than a statement. Cradle is the more conventional enterprise product: customers run the platform themselves, there is a published trust centre and security page, and coverage spans pharmaceutical, agricultural, food and chemical protein engineering. For a team that wants a tool their scientists operate across many problems, Cradle. For one whose work is antibody and binder design and who will be asked how the designs were validated, Chai has already answered.
- It is a deployed software product rather than a partnership, with customers running the platform themselves, a trust centre published at a dedicated address and a security page behind it.
- Operational evidence is specific and quantified as of a stated date rather than described in general terms, covering how the platform performs against experimental cycles.
- The applied coverage spans pharmaceutical, biotechnology, agricultural, food and chemical research, so a team can use the same platform across genuinely different protein engineering problems.
- The models are named, versioned and released publicly with a documented history, and the underlying method is described specifically rather than as generative machine learning.
- Wet laboratory validation is quantified with its design stated, including the number of targets attempted and the number of designs tested, which is the disclosure this category most often avoids.
- The most complete governance posture in this category, and the only one backed by a costly action rather than a policy statement, which matters in a field where the designs are novel antibodies and binders.
Side by Side
| Axis | C Chai Discovery |
C Cradle |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The two operate different deployment models and a buyer's exposure differs accordingly: Cradle sells software the customer runs, while Chai operates two distinct deployment positions whose terms differ, so establish which one you are contracting for before comparing anything else. Neither publishes pricing. Cradle publishes no formal governance framework, model card or bias disclosure, which is the gap against Chai's position. Neither company's designs have been established in humans, so all evidence here is molecular and preclinical and should not be read as clinical validation.